Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 2 ( February, 2021 ) > List of Articles


Renal Dysfunction in Cirrhosis: Critical Care Management

Akila Rajakumar, Ellango Appuswamy, Ilankumaran Kaliamoorthy, Mohamed Rela

Keywords : Acute kidney injury in cirrhosis, Dialysis in cirrhosis, Hepatorenal syndrome, Renal dysfunction in cirrhosis, Renal replacement therapy in cirrhosis, Volume overload in cirrhosis

Citation Information : Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021; 25 (2):207-214.

DOI: 10.5005/jp-journals-10071-23721

License: CC BY-NC 4.0

Published Online: 22-02-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Cirrhotic patients with manifestations of the end-stage liver disease have a high risk for developing renal dysfunction even with minor insults. The development of renal dysfunction increases the morbidity and mortality of these patients. Causes of renal dysfunction in cirrhotics can be due to hepatorenal syndrome (HRS) or acute kidney injury (AKI) resulting from prerenal, renal, and postrenal causes. Development of pretransplant renal dysfunction has been shown to affect post-liver transplantation outcomes. Early detection and aggressive strategies for the prevention of further progression of renal dysfunction seem to decrease the morbidity and improve survival in this group of patients. This article aims to outline the pathogenesis of renal dysfunction in cirrhosis, etiological factors, and evaluation of renal dysfunction, strategies for aggressive therapy for renal dysfunction, the indications of renal replacement therapy (RRT) in this group of patients, and the various modalities of RRT with their merits and demerits. A thorough understanding of the pathogenesis, early detection, and aggressive corrective measures for AKI can prevent further progression. In conclusion, a good knowledge of treatment modalities available for renal dysfunction in cirrhosis and institution of timely interventions can significantly improve survival in this group of patients.

PDF Share
  1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44(1):217–231. DOI: 10.1016/j.jhep.2005.10.013.
  2. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005;31(12):1693–1699. DOI: 10.1007/s00134-005-2842-7.
  3. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37(2):233–243. DOI: 10.1053/jhep.2003.50084.
  4. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59(3):361–365.
  5. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006;6(11):2651–2659. DOI: 10.1111/j.1600-6143.2006.01526.x.
  6. Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology 2007;45(3):797–805. DOI: 10.1002/hep.21563.
  7. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35(5):1179–1185. DOI: 10.1053/jhep.2002.33160.
  8. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279–1290. DOI: 10.1056/NEJMra0809139.
  9. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23(1):164–176. DOI: 10.1002/hep.510230122.
  10. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339(8):533–541. DOI: 10.1056/NEJM199808203390807.
  11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8(5):1151–1157. DOI: 10.1002/hep.1840080532.
  12. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122(1):85–93. DOI: 10.1053/gast.2002.30305.
  13. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008;28(1):3–25. DOI: 10.1055/s-2008-1040318.
  14. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105(1):229–236. DOI: 10.1016/0016-5085(93)90031-7.
  15. Munoz SJ. The hepatorenal syndrome. Med Clin North Am 2008;92(4):813–837, viii–ix. DOI: 10.1016/j.mcna.2008.03.007.
  16. Pichler RH, Huskey J, Kowalewska J, Moiz A, Perkins J, Davis CL, et al. Kidney biopsies may help predict renal function after liver transplantation. Transplantation 2016;100(10):2122–2128. DOI: 10.1097/TP.0000000000001334.
  17. Jamieson NV, European PH1 Transplantation Study Group. A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984–2004. Am J Nephrol 2005;25:282–289. DOI: 10.1159/000086359.
  18. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56(9):1310–1318. DOI: 10.1136/gut.2006.107789.
  19. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380(9843):756–766. DOI: 10.1016/S0140-6736(11)61454-2.
  20. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. DOI: 10.1186/cc5713.
  21. Bories PN, Campillo B, Azaou L, Scherman E. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997;25(6):1328–1333. DOI: 10.1002/hep.510250604.
  22. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001;96(7):2206–2210. DOI: 10.1111/j.1572-0241.2001.03958.x.
  23. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Munoz A, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int2009;29(3):415–419. DOI: 10.1111/j.1478-3231.2008.01877.x.
  24. Biyik M, Ataseven H, Biyik Z, Asil M, Cifci S, Sayin S, et al. KDIGO (Kidney Disease: Improving Global Outcomes) criteria as a predictor of hospital mortality in cirrhotic patients. Turk J Gastroenterol 2016;27(2):173–179. DOI: 10.5152/tjg.2016.15467.
  25. Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012;56(4):810–818. DOI: 10.1016/j.jhep.2011.10.016.
  26. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013;57(2):753–762. DOI: 10.1002/hep.25735.
  27. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42(2):439–447. DOI: 10.1002/hep.20766.
  28. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994;154(2):201–205. DOI: 10.1001/archinte.1994.00420020117013.
  29. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010;52(4):605–613. DOI: 10.1016/j.jhep.2009.11.025.
  30. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362(9398):1819–1827. DOI: 10.1016/S0140-6736(03)14903-3.
  31. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365(9466):1231–1238. DOI: 10.1016/S0140-6736(05)74811-X.
  32. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105(3):485–491. DOI: 10.1097/00000542-200609000-00011.
  33. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40(2):221–226. DOI: 10.1053/ajkd.2002.34487.
  34. Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011;23(2):194–200. DOI: 10.1097/MOP.0b013e328343f4dd.
  35. Omar M, Abdel-Razek W, Abo-Raia G, Assem M, El-Azab G. Evaluation of serum cystatin C as a marker of early renal impairment in patients with liver cirrhosis. Int J Hepatol 2015;2015:309042. DOI: 10.1155/2015/309042.
  36. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002;50(1):106–110. DOI: 10.1136/gut.50.1.106.
  37. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014;60(2):622–632. DOI: 10.1002/hep.26980.
  38. Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol 2009;23(6):441–445. DOI: 10.1155/2009/591317.
  39. Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016;64(3):717–735. DOI: 10.1016/j.jhep.2015.10.019.
  40. Baradarian R, Ramdhaney S, Chapalamadugu R, Skoczylas L, Wang K, et al. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroenterol 2004;99(4):619–622. DOI: 10.1111/j.1572-0241.2004.04073.x.
  41. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20(6):1495–1501. DOI: 10.1002/hep.1840200619.
  42. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341(6):403–409. DOI: 10.1056/NEJM199908053410603.
  43. Cardenas A, Gines P. Management of patients with cirrhosis awaiting liver transplantation. Gut 2011;60(3):412–421. DOI: 10.1136/gut.2009.179937.
  44. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134(1):111–119. DOI: 10.1053/j.gastro.2007.10.055.
  45. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46(5):935–946. DOI: 10.1016/j.jhep.2007.02.001.
  46. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53(3):830–835. DOI: 10.1007/s10620-007-9919-9.
  47. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134(5):1352–1359. DOI: 10.1053/j.gastro.2008.02.024.
  48. Brinch K, Moller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39(1):24–31. DOI: 10.1016/s0168-8278(03)00160-0.
  49. Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 2008;12(2):R34. DOI: 10.1186/cc6812.
  50. Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol 2015;15:167. DOI: 10.1186/s12876-015-0389-9.
  51. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011;58(6):928–938. DOI: 10.1053/j.ajkd.2011.07.017.
  52. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134(5):1360–1368. DOI: 10.1053/j.gastro.2008.02.014.
  53. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51(2):576–584. DOI: 10.1002/hep.23286.
  54. Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2011;43(1):175–184. DOI: 10.1007/s11255-010-9725-8.
  55. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016;63(3):983–992. DOI: 10.1002/hep.28396.
  56. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010;25(5):880–885. DOI: 10.1111/j.1440-1746.2009.06132.x.
  57. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36(2):374–380. DOI: 10.1053/jhep.2002.34343.
  58. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56(6):1293–1298. DOI: 10.1016/j.jhep.2012.01.012.
  59. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47(4):499–505. DOI: 10.1016/j.jhep.2007.04.010.
  60. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103(7):1689–1697. DOI: 10.1111/j.1572-0241.2008.01828.x.
  61. Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014;9(9):e107466. DOI: 10.1371/journal.pone.0107466.
  62. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011;55(6):1241–1248. DOI: 10.1016/j.jhep.2011.03.012.
  63. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother 2009;43(4):692–699. DOI: 10.1345/aph.1L373.
  64. Tavakkoli H, Yazdanpanah K, Mansourian M. Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med 2012;3(11):764–769.
  65. Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015;62(2):567–574. DOI: 10.1002/hep.27709.
  66. Lee JP, Kwon HY, Park JI, Yi NJ, Suh KS, Lee HW, et al. Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation. Liver Transpl 2012;18(10):1237–1244. DOI: 10.1002/lt.23493.
  67. Xu X, Ling Q, Zhang M, Gao F, He Z, You J, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation 2009;87(10):1514–1519. DOI: 10.1097/TP.0b013e3181a4430b.
  68. Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, et al. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 2012;12(11):2901–2908. DOI: 10.1111/j.1600-6143.2012.04190.x.
  69. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury-Section 5: Dialysis Interventions for Treatment of AKI. Kidney Int Suppl 2012;2(1):89–115. DOI: 10.1038/kisup.2011.35.
  70. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008;12(3):R74. DOI: 10.1186/cc6916.
  71. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49(6):675–683. DOI: 10.1016/j.jacc.2006.07.073.
  72. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009;76(4):422–427. DOI: 10.1038/ki.2009.159.
  73. Bouffard Y, Viale JP, Annat G, Delafosse B, Guillaume C, Motin J. Energy expenditure in the acute renal failure patient mechanically ventilated. Intensive Care Med 1987;13(6):401–404. DOI: 10.1007/BF00257684.
  74. Bellomo R, Ronco C. Continuous haemofiltration in the intensive care unit. Crit Care 2000;4(6):339–345. DOI: 10.1186/cc718
  75. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34(1):17–60. DOI: 10.1007/s00134-007-0934-2.
  76. Servillo G, Vargas M, Pastore A, Procino A, Iannuzzi M, Capuano A, et al. Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data. Biomed Res Int 2013;2013:108951. DOI: 10.1155/2013/108951.
  77. Ronco C, Bonello M, Bordoni V, Ricci Z, D'Intini V, Bellomo R, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004;22(1):164–174. DOI: 10.1159/000074937.
  78. Phu NH, Hien TT, Mai NT, Chau TT, Chuong LV, Loc PP, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002;347(12):895–902. DOI: 10.1056/NEJMoa020074.
  79. Gabriel DP, Caramori JT, Martim LC, Barretti P, Balbi AL. High volume peritoneal dialysis vs daily hemodialysis: a randomized, controlled trial in patients with acute kidney injury. Kidney Int Suppl 2008;(108):S87–S93. DOI: 10.1038/
  80. Guest S. Peritoneal dialysis in patients with cirrhosis and ascites. Adv Perit Dial 2010;26:82–87.
  81. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis 2001;37(3):457–466.
  82. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta RL, et al. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol 2008;3(3):869–875. DOI: 10.2215/CJN.04821107.
  83. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 1993;41:S245–S251.
  84. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med 2008;36(2):610–617. DOI: 10.1097/01.CCM.0B013E3181611F552.
  85. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581–1589. DOI: 10.1056/NEJM200005253422107.
  86. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4(8):1522–1530.
  87. Baldwin I, Bellomo R, Naka T, Koch B, Fealy N. A pilot randomized controlled comparison of extended daily dialysis with filtration and continuous veno-venous hemofiltration: fluid removal and hemodynamics. Int J Artif Organs 2007;30(12):1083–1089. DOI: 10.1177/039139880703001208.
  88. Baldwin I, Naka T, Koch B, Fealy N, Bellomo R. A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance. Intensive Care Med 2007;33(5):830–835. DOI: 10.1007/s00134-007-0596-0.
  89. Marshall MR, Creamer JM, Foster M, Ma TM, Mann SL, Fiaccadori E, et al. Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011;26(7):2169–2175. DOI: 10.1093/ndt/gfq694.
  90. Fieghen HE, Friedrich JO, Burns KE, Nisenbaum R, Adhikari NK, Hladunewich MA, et al. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol 2010;11:32. DOI: 10.1186/1471-2369-11-32.
  91. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA, Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure I. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail 2010;16(4):277–284. DOI: 10.1016/j.cardfail.2009.12.009.
  92. Wen H, Zhang Y, Zhu J, Lan Y, Yang H. Ultrafiltration versus intravenous diuretic therapy to treat acute heart failure: a systematic review. Am J Cardiovasc Drugs 2013;13(5):365–373. DOI: 10.1007/s40256-013-0034-3.
  93. Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46(11):2043–2046. DOI: 10.1016/j.jacc.2005.05.098.
  94. Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016;375(2):122–133. DOI:10.1056/NEJMoa1603017.
  95. McLean AG, Davenport A, Cox D, Sweny P. Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction. Kidney Int 2000;58(4):1765–1772. DOI: 10.1046/j.1523-1755.2000.00338.x.
  96. Thomas AN, Guy JM, Kishen R, Geraghty IF, Bowles BJ, Vadgama P. Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients. Nephrol Dial Transplant 1997;12(6):1212–1217. DOI: 10.1093/ndt/12.6.1212.
  97. Tan HK, Uchino S, Bellomo R. The acid-base effects of continuous hemofiltration with lactate or bicarbonate buffered replacement fluids. Int J Artif Organs 2003;26(6):477–483. DOI: 10.1177/039139880302600605.
  98. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361(17):1627–1638. DOI: 10.1056/NEJMoa0902413.
  99. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20. DOI: 10.1056/NEJMoa0802639.
  100. Bikhchandani J, Metcalfe M, Illouz S, Puls F, Dennison A. Extracorporeal liver perfusion system for artificial liver support across a membrane. J Surg Res 2011;171(1):e139–147. DOI: 10.1016/j.jss.2011.07.014.
  101. Chua HR, Baldwin I, Bailey M, Subramaniam A, Bellomo R. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure. J Crit Care 2012;27(6):744.e7–744.e15. DOI: 10.1016/j.jcrc.2012.08.016.
  102. Agarwal B, Shaw S, Shankar Hari M, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol 2009;51(3):504–509. DOI: 10.1016/j.jhep.2009.05.028.
  103. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003;16(4):566–571.
  104. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003;31(10):2450–2455. DOI: 10.1097/01.CCM.0000084871.76568.E6.
  105. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997;109(4):123–127.
  106. Durao MS, Monte JC, Batista MC, Oliveira M, Iizuka IJ, Santos BF, et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008;36(11):3024–3029. DOI: 10.1097/CCM.0b013e31818b9100.
  107. Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015;19():349. DOI: 10.1186/s13054-015-1066-7.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.